Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 9(1): 9225, 2019 06 25.
Article in English | MEDLINE | ID: mdl-31239528

ABSTRACT

While cerebellar alterations may play a crucial role in the development of core autism spectrum disorder (ASD) symptoms, their pathophysiology on the function of cerebrocerebellar circuit loops is largely unknown. We combined multimodal MRI (9.4 T) brain assessment of the prenatal rat valproate (VPA) model and correlated immunohistological analysis of the cerebellar Purkinje cell number to address this question. We hypothesized that a suitable functional MRI (fMRI) paradigm might show some altered activity related to disrupted cerebrocerebellar information processing. Two doses of maternal VPA (400 and 600 mg/kg, s.c.) were used. The higher VPA dose induced 3% smaller whole brain volume, the lower dose induced 2% smaller whole brain volume and additionally a focal gray matter density decrease in the cerebellum and brainstem. Increased cortical BOLD responses to whisker stimulation were detected in both VPA groups, but it was more pronounced and extended to cerebellar regions in the 400 mg/kg VPA group. Immunohistological analysis revealed a decreased number of Purkinje cells in both VPA groups. In a detailed analysis, we revealed that the Purkinje cell number interacts with the cerebral BOLD response distinctively in the two VPA groups that highlights atypical function of the cerebrocerebellar circuit loops with potential translational value as an ASD biomarker.


Subject(s)
Autistic Disorder/pathology , Purkinje Cells/pathology , Valproic Acid/adverse effects , Animals , Autistic Disorder/chemically induced , Autistic Disorder/diagnostic imaging , Autistic Disorder/physiopathology , Calbindins/metabolism , Cell Count , Disease Models, Animal , Female , Magnetic Resonance Imaging , Purkinje Cells/drug effects , Rats , Rats, Sprague-Dawley
2.
PLoS One ; 13(5): e0198265, 2018.
Article in English | MEDLINE | ID: mdl-29851990

ABSTRACT

Bilateral common carotid artery occlusion (BCCAo) in the rat is a widely used animal model of vascular dementia and a valuable tool for preclinical pharmacological drug testing, although the varying degrees of acute focal ischemic lesions it induces could interfere with its translational value. Recently, a modification to the BCCAo model, the stepwise occlusion of the two carotid arteries, has been introduced. To acquire objective translatable measures, we used longitudinal multimodal magnetic resonance imaging (MRI) to assess the effects of semi-chronic (8 days) donepezil treatment in this model, with half of the Wistar rats receiving the treatment one week after the stepwise BCCAo. With an ultrahigh field MRI, we measured high-resolution anatomy, diffusion tensor imaging, cerebral blood flow measurements and functional MRI in response to whisker stimulation, to evaluate both the structural and functional effects of the donepezil treatment and stepwise BCCAo up to 5 weeks post-occlusion. While no large ischemic lesions were detected, atrophy in the striatum and in the neocortex, along with widespread white matter microstructural changes, were found. Donepezil ameliorated the transient drop in the somatosensory BOLD response in distant cortical areas, as detected 2 weeks after the occlusion but the drug had no effect on the long term structural changes. Our results demonstrate a measurable functional MRI effect of the donepezil treatment and the importance of diffusion MRI and voxel based morphometry (VBM) analysis in the translational evaluation of the rat BCCAo model.


Subject(s)
Carotid Artery, Common/diagnostic imaging , Carotid Stenosis/pathology , Carotid Stenosis/physiopathology , Cerebrovascular Circulation/drug effects , Diffusion Tensor Imaging , Indans/pharmacology , Piperidines/pharmacology , White Matter/pathology , Animals , Brain Ischemia/complications , Carotid Artery, Common/drug effects , Carotid Artery, Common/physiopathology , Carotid Stenosis/complications , Carotid Stenosis/diagnostic imaging , Donepezil , Male , Oxygen/blood , Rats , Rats, Wistar , White Matter/drug effects
3.
Neuroscience ; 344: 133-147, 2017 03 06.
Article in English | MEDLINE | ID: mdl-28003158

ABSTRACT

Central sensitization is a key mechanism in the pathology of several neuropathic pain disorders. We aimed to investigate the underlying brain connectivity changes in a rat model of chronic pain. Non-noxious whisker stimulation was used to evoke blood-oxygen-level-dependent (BOLD) responses in a block-design functional Magnetic Resonance Imaging (fMRI) experiment on 9.4T. Measurements were repeated two days and one week after injecting complete Freund's adjuvant into the rats' whisker pad. We found that acute pain reduced activation in the barrel cortex, most probably due to a plateau effect. After one week, increased activation of the anterior cingulate cortex was found. Analyses of effective connectivity driven by stimulus-related activation revealed that chronic pain-related central sensitization manifested as a widespread alteration in the activity of the somatosensory network. Changes were mainly mediated by the anterior cingulate cortex and the striatum and affected the somatosensory and motor cortices and the superior colliculus. Functional connectivity analysis of nested BOLD oscillations justified that the anterior cingular-somatosensory interplay is a key element of network changes. Additionally, a decreased cingulo-motor functional connectivity implies that alterations also involve the output tract of the network. Our results extend the knowledge about the role of the cingulate cortex in the chronification of pain and indicate that integration of multiple connectivity analysis could be fruitful in studying the central sensitization in the pain matrix.


Subject(s)
Central Nervous System Sensitization/physiology , Chronic Pain/physiopathology , Gyrus Cinguli/physiopathology , Inflammation/physiopathology , Animals , Brain Mapping , Cerebrovascular Circulation/physiology , Chronic Pain/diagnostic imaging , Disease Models, Animal , Gyrus Cinguli/diagnostic imaging , Inflammation/diagnostic imaging , Magnetic Resonance Imaging , Male , Neural Pathways/diagnostic imaging , Neural Pathways/physiopathology , Oxygen/blood , Rats, Sprague-Dawley , Trigeminal Ganglion/physiopathology , Trigeminal Nerve/physiopathology , Vibrissae/physiology
4.
PLoS One ; 10(11): e0142190, 2015.
Article in English | MEDLINE | ID: mdl-26540189

ABSTRACT

BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. MATERIALS AND METHODS: We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 µg bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 µg bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. RESULTS: In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p = 0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. CONCLUSION: Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Bevacizumab/pharmacology , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/pathology , Tumor Burden/drug effects , Angiogenesis Inhibitors/pharmacology , Animals , Cell Line, Tumor , Disease Models, Animal , HT29 Cells , Humans , Male , Mice , Mice, Inbred C57BL , Non-Randomized Controlled Trials as Topic , Treatment Outcome
5.
J Psychopharmacol ; 29(4): 447-55, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25586394

ABSTRACT

There is a huge unmet need to understand and treat pathological cognitive impairment. The development of disease modifying cognitive enhancers is hindered by the lack of correct pathomechanism and suitable animal models. Most animal models to study cognition and pathology do not fulfil either the predictive validity, face validity or construct validity criteria, and also outcome measures greatly differ from those of human trials. Fortunately, some pharmacological agents such as scopolamine evoke similar effects on cognition and cerebral circulation in rodents and humans and functional MRI enables us to compare cognitive agents directly in different species. In this paper we report the validation of a scopolamine based rodent pharmacological MRI provocation model. The effects of deemed procognitive agents (donepezil, vinpocetine, piracetam, alpha 7 selective cholinergic compounds EVP-6124, PNU-120596) were compared on the blood-oxygen-level dependent responses and also linked to rodent cognitive models. These drugs revealed significant effect on scopolamine induced blood-oxygen-level dependent change except for piracetam. In the water labyrinth test only PNU-120596 did not show a significant effect. This provocational model is suitable for testing procognitive compounds. These functional MR imaging experiments can be paralleled with human studies, which may help reduce the number of false cognitive clinical trials.


Subject(s)
Cognition Disorders/drug therapy , Magnetic Resonance Imaging/methods , Nootropic Agents/pharmacology , Scopolamine/toxicity , Animals , Cognition Disorders/physiopathology , Disease Models, Animal , Male , Maze Learning/drug effects , Oxygen/blood , Rats , Rats, Wistar , Species Specificity
6.
Brain Res ; 1583: 1-11, 2014 Oct 02.
Article in English | MEDLINE | ID: mdl-24976584

ABSTRACT

The mesocortical dopaminergic pathway projecting from the ventral tegmental area (VTA) to the prefrontal cortex (PFC) contributes to the processing of reward signals. This pathway is regulated by gonadal steroids including estradiol. To address the putative role of estradiol and isotype-selective estrogen receptor (ER) agonists in the regulation of the rodent mesocortical system, we combined fMRI, HPLC-MS and qRT-PCR techniques. In fMRI experiments adult, chronically ovariectomized rats, treated with either vehicle, estradiol, ERα agonist 16α-lactone-estradiol (LE2) or ERß agonist diarylpropionitrile (DPN), received a single dose of d-amphetamine-sulphate (10mg/kg, i.p.) and BOLD responses were monitored in the VTA and the PFC. Ovariectomized rats showed no significant response to amphetamine. In contrast, the VTA of ER agonist-substituted ovariectomized rats showed robust amphetamine-evoked BOLD increases. The PFC of estradiol-replaced animals was also responsive to amphetamine. Mass spectroscopic analysis of dopamine and its metabolites revealed a two-fold increase in both dopamine and 3,4-dihydroxyphenylacetic acid content of the PFC in estradiol-replaced animals compared to ovariectomized controls. qRT-PCR studies revealed upregulation of dopamine transporter and dopamine receptor in the VTA and PFC, respectively, of ER agonist-treated ovariectomized animals. Collectively, the results indicate that E2 and isotype-selective ER agonists can powerfully modulate the responsiveness of the mesocortical dopaminergic system, increase the expression of key genes related to dopaminergic neurotransmission and augment the dopamine content of the PFC. In a broader sense, the findings support the concept that the manifestation of reward signals in the PFC is dependent on the actual estrogen milieu of the brain.


Subject(s)
Estradiol/pharmacology , Estrogens/pharmacology , Prefrontal Cortex/drug effects , Ventral Tegmental Area/drug effects , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Cerebrovascular Circulation/drug effects , Cerebrovascular Circulation/physiology , Dextroamphetamine/pharmacology , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/pharmacology , Estrogen Receptor alpha/agonists , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/agonists , Estrogen Receptor beta/metabolism , Female , Lactones/pharmacology , Nitriles/pharmacology , Ovariectomy , Oxygen/blood , Prefrontal Cortex/physiology , Propionates/pharmacology , Rats, Wistar , Receptors, Dopamine/metabolism , Ventral Tegmental Area/physiology
7.
PLoS One ; 9(5): e97651, 2014.
Article in English | MEDLINE | ID: mdl-24830778

ABSTRACT

The orexigenic gut-brain peptide, ghrelin and its G-protein coupled receptor, the growth hormone secretagogue receptor 1a (GHS-R1A) are pivotal regulators of hypothalamic feeding centers and reward processing neuronal circuits of the brain. These systems operate in a cooperative manner and receive a wide array of neuronal hormone/transmitter messages and metabolic signals. Functional magnetic resonance imaging was employed in the current study to map BOLD responses to ghrelin in different brain regions with special reference on homeostatic and hedonic regulatory centers of energy balance. Experimental groups involved male, ovariectomized female and ovariectomized estradiol-replaced rats. Putative modulation of ghrelin signaling by endocannabinoids was also studied. Ghrelin-evoked effects were calculated as mean of the BOLD responses 30 minutes after administration. In the male rat, ghrelin evoked a slowly decreasing BOLD response in all studied regions of interest (ROI) within the limbic system. This effect was antagonized by pretreatment with GHS-R1A antagonist JMV2959. The comparison of ghrelin effects in the presence or absence of JMV2959 in individual ROIs revealed significant changes in the prefrontal cortex, nucleus accumbens of the telencephalon, and also within hypothalamic centers like the lateral hypothalamus, ventromedial nucleus, paraventricular nucleus and suprachiasmatic nucleus. In the female rat, the ghrelin effects were almost identical to those observed in males. Ovariectomy and chronic estradiol replacement had no effect on the BOLD response. Inhibition of the endocannabinoid signaling by rimonabant significantly attenuated the response of the nucleus accumbens and septum. In summary, ghrelin can modulate hypothalamic and mesolimbic structures controlling energy balance in both sexes. The endocannabinoid signaling system contributes to the manifestation of ghrelin's BOLD effect in a region specific manner. In females, the estradiol milieu does not influence the BOLD response to ghrelin.


Subject(s)
Brain/pathology , Gene Expression Regulation , Ghrelin/metabolism , Homeostasis , Magnetic Resonance Imaging , Animals , Brain/metabolism , Estradiol/metabolism , Feeding Behavior , Female , Hypothalamus/metabolism , Hypothalamus/pathology , Limbic System/physiology , Male , Nucleus Accumbens/pathology , Paraventricular Hypothalamic Nucleus/pathology , Prefrontal Cortex/pathology , Rats , Rats, Wistar , Receptor, Cannabinoid, CB1/metabolism , Reward , Signal Transduction , Suprachiasmatic Nucleus/pathology , Time Factors
8.
J Cereb Blood Flow Metab ; 34(6): 995-1000, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24643080

ABSTRACT

Concordant results of functional magnetic resonance imaging (fMRI) and behavioral tests prove that some non-blood-brain barrier-penetrating drugs produce robust central nervous system (CNS) effects. The anticholinergic scopolamine interferes with learning when tested in rats, which coincides with a negative blood-oxygen-level-dependent (BOLD) change in the prefrontal cortex (PFC) as demonstrated by fMRI. The peripherally acting butylscopolamine also evokes a learning deficit in a water-labyrinth test and provokes a negative BOLD signal in the PFC. Donepezil-a highly CNS-penetrating cholinesterase inhibitor-prevents the negative BOLD and cognitive deficits regardless whether the provoking agent is scopolamine or butylscopolamine. Interestingly, the non-BBB-penetrating cholinesterase inhibitor neostigmine also prevents or substantially inhibits those cognitive and fMRI changes. Intact cerebral blood flow and optimal metabolism are crucial for the normal functioning of neurons and other cells in the brain. Drugs that are not BBB penetrating yet act on the CNS highlight the importance of unimpaired circulation, and point to the cerebral vasculature as a primary target for drug action in diseases where impaired circulation and consequently suboptimal energy metabolism are followed by upstream pathologic events.


Subject(s)
Blood-Brain Barrier , Cholinesterase Inhibitors/pharmacology , Cognition/drug effects , Magnetic Resonance Imaging , Neostigmine/pharmacology , Animals , Blood-Brain Barrier/diagnostic imaging , Blood-Brain Barrier/metabolism , Cholinesterase Inhibitors/pharmacokinetics , Neostigmine/pharmacokinetics , Radiography , Rats
9.
Brain Res Bull ; 99: 34-40, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24099980

ABSTRACT

Tolperisone is a voltage gated sodium channel blocker, centrally acting muscle relaxant drug, with a very advantageous side effect profile. Like other sodium channel blockers, it has weak affinity to the resting state and high affinity to the open/inactivated state of the channel. In this paper, its effect on BOLD responses in rat brain were elucidated both on the resting brain and paw stimulation evoked BOLD responses. Tolperisone did not exert any visible effect on resting brain, but strongly inhibited the paw stimulation evoked BOLD responses, showing somewhat higher efficacy in brain areas involved in pain sensation. This finding is in a good agreement with its sodium channel blocking profile. In the resting brain, most of the channels are in resting state. Electric train stimuli of the paw results in over activated neurons, where most sodium channels are in open or inactivated state. These data suggest that the very advantageous profile of tolperisone can be explained by its selective action on open or inactivated sodium channels of over-activated neurons in various brain regions rather than by a selective effect in the spinal cord as suggested previously.


Subject(s)
Brain/blood supply , Brain/drug effects , Magnetic Resonance Imaging , Muscle Relaxants, Central/pharmacology , Rest , Tolperisone/pharmacology , Anesthetics, Inhalation/pharmacology , Animals , Electric Stimulation , Image Processing, Computer-Assisted , Isoflurane/pharmacology , Male , Oxygen/blood , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...